Purdue University, Eli Lilly and Co., and Merck & Co. have launched the Young Institute Pharmaceutical Manufacturing Consortium, a collaborative effort to pioneer advances in making medicines. Operating within Purdue’s William D. and Sherry L. Young Institute for Advanced Manufacturing of Pharmaceuticals, consortium partners will focus on advancing pharmaceutical manufacturing, according to a Jan. 17 news…
Merck’s Q3 2023 revenue guidance put it in line with Pfizer’s
Merck & Co. has announced its third quarter results, projectings its full-year 2023 revenue to be in the range of $59.7 billion to $60.2 billion. That’s roughly in line with the guidance from Pfizer, which recently adjusted its revenue forecast from $58 billion to $61 billion. As Pfizer deals with reduced demand for COVID-19 products,…
Sanofi, Merck and Novartis top pharma M&A in recent years
Despite a temporary slowdown during the early days of the pandemic, the pharma sector has witnessed a steady rise in M&A activity over the years. The number of deals climbed from 23 in 2018 to 43 in 2022. Major players driving this trend include Sanofi, Merck & Co. and Novartis. Those three players have made…
Exploring Merck’s key arguments in its constitutional challenge against the Inflation Reduction Act
In a strong move against the federal government, Merck & Co., based in Kenilworth, New Jersey, has launched a lawsuit against the Inflation Reduction Act (IRA). The firm has retained the services of prominent law firm Jones Day, at times known for its assertive litigation style. In recent years, the firm has also been involved…
Moderna names former Merck exec as new chief commercial officer
COVID-19 vaccine developer Moderna (Nasdaq:MRNA) has named Arpa Garay as its chief commercial officer starting May 31, 2022. Garay spent more than 15 years at Merck & Co. (NYSE:MRK). In February, she was promoted to the post of chief marketing officer for Merck’s human health division. Garay also was a member of the company’s executive…
President Biden vows to make aggressive use of Pfizer’s COVID-19 antiviral
President Biden said in his State of the Union address that the U.S. aims to ramp up the use of Pfizer‘s (NYSE:PFE) Plaxovid. The treatment has been in short supply since it won emergency use authorization late last year. Last year, when Merck & Co. (NYSE: MRK) and Pfizer were close to winning regulatory authorization for…